Terry Rosen is looking to leave the thundering herd and blaze a new trail in PD-1 R&D
Who needs another PD-1 checkpoint inhibitor?
There are 6 on the US market, plus a bunch coming in from China, with GlaxoSmithKline among the major players — Novartis, etc — looking to craft their own R&D strategy that can carve into the field. Merck’s dominant Keytruda is now officially in more than 1,000 clinical trials, including a string of combo studies.
So how does a relatively small biotech like Arcus Biosciences compete with a PD-1 licensed from China’s WuXi in a deal fronted with just $18.5 million?
Basic subscription required
Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.